Annexon Inc (ANNX)

Apr 16, 2025, 4:05 PM EDT - 7 days ago

Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

Apr 15, 2025, 7:12 AM EDT - 8 days ago

Annexon: With IGOS Study Completion, Pre-BLA Meeting In 1st Half 2025 On Deck

Apr 8, 2025, 4:05 PM EDT - 15 days ago

Annexon Highlights Pivotal Data on First Potential Targeted Therapy for Guillain-Barré Syndrome (GBS) and Showcases New GBS Education Campaign at American Academy of Neurology (AAN) 2025 Annual Meeting

Apr 3, 2025, 6:18 PM EDT - 20 days ago

Annexon Highlights Leadership in Advancing Clinical Research and Education for Guillain-Barré Syndrome (GBS) at American Academy of Neurology (AAN) 2025 Annual Meeting

Mar 3, 2025, 8:00 AM EST - 7 weeks ago

Annexon Reports Fourth Quarter and Year-End 2024 Financial Results, Portfolio Progress and Key Anticipated Milestones

Feb 26, 2025, 4:05 PM EST - 2 months ago

Annexon Biosciences to Present at the TD Cowen 45th Annual Health Care Conference

Feb 18, 2025, 8:00 AM EST - 2 months ago

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

Feb 13, 2025, 8:30 AM EST - 2 months ago

Annexon Announces Presentations Highlighting ANX007 Functional and Structural Differentiation in Geographic Atrophy at the Macula Society 48th Annual Meeting

Jan 7, 2025, 8:00 AM EST - 3 months ago

Annexon Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 16, 2024, 7:30 AM EST - 4 months ago

Annexon Announces Positive Topline Results from Real-World Evidence Study Comparing ANX005 Treatment to Intravenous Immunoglobulin (IVIg) or Plasma Exchange (PE) in a Matched Patient Cohort for the Treatment of Guillain-Barré Syndrome (GBS)

Nov 14, 2024, 8:00 AM EST - 5 months ago

Annexon Reports Third Quarter 2024 Portfolio and Financial Results, and Key Anticipated Milestones

Nov 13, 2024, 4:05 PM EST - 5 months ago

Annexon Biosciences to Present at the Jefferies London Healthcare Conference

Oct 21, 2024, 8:00 PM EDT - 6 months ago

Annexon Presents Phase 2 Vision Preservation Data with ANX007 in Dry AMD Patients with Less Advanced GA at the American Academy of Ophthalmology 2024 Meeting

Oct 3, 2024, 1:20 AM EDT - 7 months ago

Director William Carson Acquires 3,200 Shares of Annexon Inc (ANNX)

Aug 17, 2024, 9:28 AM EDT - 8 months ago

Speculative "Buy" Rating On Annexon: Evaluating The Potential Of ANX005 For GBS

Jul 11, 2024, 6:09 PM EDT - 10 months ago

Annexon to Present Additional Phase 2 Data Showing Preservation of Visual Function and Structure by ANX007 in Geographic Atrophy at the 42nd ASRS Annual Scientific Meeting

Jun 25, 2024, 5:00 PM EDT - 10 months ago

Annexon Presented Additional Positive Phase 3 Results for ANX005 C1q-Targeted Immunotherapy in Guillain-Barré Syndrome at the 2024 PNS Annual Meeting

Jun 5, 2024, 11:04 PM EDT - 11 months ago

Annexon Announces Pricing of $125 Million Underwritten Public Offering

Jun 4, 2024, 5:06 PM EDT - 11 months ago

Annexon Announces Proposed Public Offering of Common Stock

Jun 4, 2024, 2:07 PM EDT - 11 months ago

Annexon: Complement Inhibition Of GBS Only The Beginning With Strong Tech In Place

Jun 4, 2024, 7:11 AM EDT - 11 months ago

Annexon's neurological disorder drug meets main goal of late-stage study

Jun 3, 2024, 4:30 PM EDT - 11 months ago

Annexon Biosciences to Host Conference Call and Webcast to Discuss GBS Phase 3 Data

May 13, 2024, 8:00 AM EDT - 1 year ago

Annexon Reports First Quarter 2024 Financial Results and Key Anticipated Milestones

May 9, 2024, 8:00 AM EDT - 1 year ago

Annexon Biosciences to Present at the Bank of America Health Care Conference

May 7, 2024, 12:30 PM EDT - 1 year ago

Annexon Presents New Neuroprotection Data Showing ANX007 Protects Vision and Vision-Associated Structures in Geographic Atrophy at ARVO 2024 Annual Meeting

May 1, 2024, 8:00 AM EDT - 1 year ago

Annexon to Present Data Reinforcing the Neuroprotective Effects of ANX007 and C1q Inhibition in Geographic Atrophy at the ARVO 2024 Annual Meeting

Apr 3, 2024, 8:00 AM EDT - 1 year ago

Annexon Biosciences to Present at the 23rd Annual Needham Virtual Healthcare Conference

Mar 26, 2024, 4:05 PM EDT - 1 year ago

Annexon Reports Fourth Quarter and Year-End 2023 Financial Results and Key Anticipated Milestones

Feb 27, 2024, 8:00 AM EST - 1 year ago

Annexon Biosciences to Present at the TD Cowen 44th Annual Health Care Conference

Feb 21, 2024, 8:00 AM EST - 1 year ago

Annexon to Host Virtual R&D Day on Guillain-Barré Syndrome, Focusing on its Serious Unmet Need and Annexon's Novel Therapeutic Approach

Jan 7, 2024, 8:00 PM EST - 1 year ago

Annexon Outlines 2024 Priorities with Late-Stage Clinical Milestones Across Upstream Complement Portfolio for Autoimmune, Ophthalmic and Neurodegenerative Diseases

Dec 27, 2023, 6:30 AM EST - 1 year ago

Annexon Biosciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Dec 23, 2023, 12:00 PM EST - 1 year ago

Annexon: ANX007 Advances Forward With Stellar Endpoint

Dec 20, 2023, 5:27 PM EST - 1 year ago

Annexon Announces Pricing of $125.0 Million Underwritten Public Offering of Common Stock

Dec 20, 2023, 5:10 PM EST - 1 year ago

Annexon Outlines Global Registrational Program for ANX007 in Geographic Atrophy with FDA Alignment on Vision Preservation as Primary Endpoint

Dec 20, 2023, 5:08 PM EST - 1 year ago

Annexon Reports Phase 1 Results for ANX1502, its Oral Small Molecule Inhibitor of the Classical Complement Pathway

Nov 22, 2023, 4:01 PM EST - 1 year ago

Annexon Biosciences to Participate in the 6th Annual Evercore ISI HealthCONx Conference

Nov 13, 2023, 6:30 AM EST - 1 year ago

Annexon Reports Significant Progress with its Priority Programs and Third Quarter 2023 Financial Results

Nov 9, 2023, 6:30 AM EST - 1 year ago

Annexon Biosciences to Participate in 2023 Jefferies London Healthcare Conference

Oct 24, 2023, 6:30 AM EDT - 1 year ago

Annexon Receives PRIME Designation from the EMA for ANX007 for the Treatment of Geographic Atrophy

Oct 10, 2023, 6:30 AM EDT - 1 year ago

Annexon Announces Clinical and Regulatory Progress for ANX005 Pivotal Program in Guillain-Barré Syndrome (GBS)

Sep 19, 2023, 6:30 AM EDT - 1 year ago

Annexon Biosciences to Participate in the 2023 Cantor Global Healthcare Conference

Aug 7, 2023, 6:30 AM EDT - 1 year ago

Annexon Highlights Recent Pipeline and Business Progress and Reports Second Quarter 2023 Financial Results

Jul 30, 2023, 12:00 PM EDT - 1 year ago

Annexon Presents ARCHER Trial Results at ASRS 2023 Highlighting Potential of ANX007 as a Differentiated Treatment for Geographic Atrophy

Jul 27, 2023, 6:30 AM EDT - 1 year ago

Annexon Biosciences Strengthens Leadership Team with Appointment of Jamie Dananberg, M.D., as Chief Medical Officer

Jul 24, 2023, 6:30 AM EDT - 1 year ago

Annexon to Report ARCHER Phase 2 Trial Results in Geographic Atrophy at ASRS 2023

Jul 14, 2023, 7:21 PM EDT - 1 year ago

Annexon: Mixed Results, Overly Strong Market Reaction

May 24, 2023, 4:01 PM EDT - 2 years ago

Annexon Topline Data from ARCHER Phase 2 Trial of ANX007 in Geographic Atrophy Demonstrated Statistically Significant, Dose-Dependent Preservation of Visual Function

May 21, 2023, 9:23 AM EDT - 2 years ago

May MDA Breakout Stocks/ETFs Week 21 - 2023: High-Frequency Gainers To Give You An Edge

ALLK EHTH FLNC

May 14, 2023, 7:47 AM EDT - 2 years ago

May MDA Breakout Stocks/ETFs Week 20 - 2023: High-Frequency Gainers To Give You An Edge

AAPL CELH CRM CVX ENPH FLNC FNGD